Trial Profile

A Randomized Prospective Evaluation of Four Injectable Neuromodulators in the Glabella Area

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 21 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Botulinum-Toxin-A (Primary) ; Botulinum-Toxin-A (Primary) ; Botulinum-Toxin-A (Primary) ; Botulinum-Toxin-A (Primary)
Indications Facial wrinkles; Glabellar lines
Focus Therapeutic Use
Acronyms JBDX

Most Recent Events

31 Jul 2025 According to the Evolus Media Release, the publication of a landmark independent study in JAMA Dermatology directly comparing four leading botulinum toxin type A products for the treatment of glabellar lines: Jeuveau (prabotulinumtoxinA-xvfs), Botox (onabotulinumtoxinA), Dysport (abobotulinumtoxinA), and Xeomin (incobotulinumtoxinA).
18 Jul 2023 Status changed from recruiting to completed.
27 Jun 2022 Planned End Date changed from 30 Jul 2023 to 30 Aug 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com